The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

The Food and Drug Administration approved Vertex Pharmaceuticals’ “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA considered the ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive ...

Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.